

e-Table 1: Drugs recommended for reimbursement by the Common Drug Review process between September 2003 and December 2005

Drug	Indication	Disease prevalence	Drug cost*	Reason given for decision
Abacavor/lamivudine	Treatment of HIV-1 infection	Common	—	No different from another, similar drug in either benefit or cost
Adalimumab	Treatment of rheumatoid arthritis	Common	\$17 160/yr	No different from another, similar drug in either benefit or cost
Almotriptan	Acute treatment of migraine	Common	—	No different from another, similar drug in either benefit or cost
Atazanavir	Treatment of HIV-1 infection	Common	—	No different from another, similar drug in either benefit or cost
Brimonidine/ timolol	Treatment of chronic open-angle glaucoma	Common	—	No different from another, similar drug in either benefit or cost
Drospirenone/ethinyl estradiol	Oral contraceptive	Common	—	No different from another, similar drug in either benefit or cost
Dutasteride	Treatment of symptomatic benign prostatic hyperplasia	Common	\$595/yr	No different from another, similar drug in either benefit or cost
Eprosartan/ hydrochlorothiazide	Treatment of mild to moderate essential hypertension	Common	—	Superior to monotherapy and slightly less costly
Erlotinib	Treatment of metastatic non-small cell lung cancer	Not known	\$71 000/life-year gained	Significant improvement of survival in some patients compared with placebo
Fosamprenavir	Treatment of HIV-1 infection	Common	—	No different from another, similar drug in either benefit or cost
Mycophenolate	Immunosuppressant for kidney transplants	Common	—	No different from another, similar drug in benefit, but lower cost
Pegfilgrastim	Treatment of neutropenia due to non-myeloid cancer chemotherapy	Common	\$9000/course of chemotherapy	No different from another, similar drug in benefit, but lower cost
Peginterferon alfa-2a/ ribavirin	Treatment of hepatitis C	Common?	—	Superior to another, similar drug in terms of benefits
Voriconazole	Treatment of invasive aspergillosis	Common	—	No different from another, similar drug in either benefit or cost

Source: Canadian Coordinating Office for Health Technology Assessment. Available: www.ccohta.ca/CDR/cdr_recommendations.cfm (accessed 2005 Dec 07).

*Estimated maximum cost.